Navigate Titan Pharmaceuticals, Inc.
Home
About
Overview
Management Team
Board of Directors
Careers
News
Overview
Press Releases
Events
Presentations
In the News
Media Resources
Investors
Overview
News / Events
Company Information
SEC Filings
Corporate Governance
Contact
Search
All SEC Filings
Home
Investors
SEC Filings
All SEC Filings
Investors
Navigate Investors
Overview
News / Events
Company Information
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Email Alerts
Tear Sheet
Contacts
RSS News Feed
All SEC Filings
Filter Filings:
View All
10-12G
10-12G/A
10-K
10-K/A
10-K405
10-Q
10-Q/A
10KSB40
10QSB
15-12B
15-12G
25
25-NSE
3
3/A
4
4/A
424B2
424B3
424B4
424B5
425
8-A12B
8-A12B/A
8-A12G
8-K
8-K/A
ARS
AW
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DEFM14A
DEFN14A
DEFR14A
DFAN14A
EFFECT
FWP
NT 10-Q
POS AM
PRE 14A
PREN14A
PRRN14A
REGDEX
RW
S-1
S-1/A
S-1MEF
S-3
S-3/A
S-8
S-8 POS
SB-2
SB-2/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
UPLOAD
Date
Form
Description
Docs
XBRL
Pages
12/15/20
EFFECT
Notice of Effectiveness
1
12/14/20
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
12/08/20
S-1
General form of registration statement for all companies including face-amount certificate companies
Related Documents
EX-5.1
EX-23.1
15
12/03/20
8-K
Current report filing
1
12/02/20
DEFA14A
Additional definitive proxy soliciting materials and Rule 14(a)(12) material
2
12/01/20
8-K
Current report filing
Related Documents
EX-3.1
EX-99.1
4
11/25/20
DEF 14A
Definitive proxy statements
43
11/16/20
10-Q
Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-10.28
EX-31.1
EX-32.1
49
11/09/20
DEFA14A
Additional definitive proxy soliciting materials and Rule 14(a)(12) material
2
11/09/20
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
8
<< Previous
1...
17
18
19
20
21
22
23
24
25
26
...106
Next >>